Kaleido Biosciences (OTC: KLDO)
Kaleido Biosciences Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Kaleido Biosciences Company Info
Kaleido Biosciences, Inc. is a clinical-stage healthcare company, which engages in the provision of healthcare services. It focuses on leveraging the microbiome organ to treat disease and improve human health. The firm offers microbiome metabolic therapies (MMT), which are designed to modulate the metabolic output and profile of the microbiome by driving the function and composition of the organ's existing microbes. The company was founded by Geoffrey von Maltzahn and Noubar B. Afeyan on January 27, 2015 and is headquartered in Lexington, MA.
News & Analysis
All the 2020 Pre-JPM News Healthcare Investors Need to Know
The Super Bowl of healthcare kicked off early for these companies.
Will the Gut Microbiome Change Medicine? Wall Street Isn't Convinced.
The potential is significant. Unfortunately, so is the hype.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.